Standout Papers

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 ... 2019 2026 2021 2023 300
  1. Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation (2019)
    Audrey Le Floc’h, Jeanne Allinne et al. Allergy

Immediate Impact

43 standout
Sub-graph 1 of 15

Citing Papers

The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma
2024 Standout
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis
2024 Standout
1 intermediate paper

Works of Dylan Birchard being referenced

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
2019 Standout
IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation
2019

Author Peers

Author Last Decade Papers Cites
Dylan Birchard 272 154 92 162 4 433
Jeanne Allinne 268 153 91 161 5 430
Regina T. Chustz 168 166 59 142 8 392
Ashraf Uzzaman 211 151 55 179 9 506
Satoko Kimura 223 90 30 215 5 385
Charles Asare 293 220 54 95 4 490
Amani El-Gammal 264 215 137 89 8 420
Graham Sturton 296 272 84 64 8 491
David Floch 122 136 44 94 5 402
Jessica Rajan 238 54 86 126 6 413
N. Zhang 280 58 119 300 7 483

All Works

Loading papers...

Rankless by CCL
2026